Skip to content

Clinical Observation on the Preventive and Therapeutic Effects of AI-Assisted Zhishanfang in Post-Endoscopic Treatment of Colorectal Adenomas

Clinical Observation on the Preventive and Therapeutic Effects of AI-Assisted Zhishanfang in Post-Endoscopic Treatment of Colorectal Adenomas

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001703
Enrollment
Unknown
Registered
2025-09-11
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal adenoma

Interventions

test group:Oral Chinese herbal medicine

Sponsors

Wangjing Hospital China Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-75 years and gender. 2)Patients diagnosed by colonoscopy within the last 6 months and confirmed pathologically by complete endoscopic removal as progressive colorectal adenoma,including villous adenoma, tubulovillous adenoma, and tubular adenoma,and histologically confirmed presence of 1-6 colorectal adenomas. 3)With or without one of the symptoms of constipation diarrhea or bloating. 4)Bowel cleanliness Boston score = 6. 5)Familial colorectal adenomas or polyposis excluded by taking medical and family history. 6)Those who volunteered to be tested and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) previous colonoscopy in which the adenoma was not completely removed; 2)those with polyps that have become cancerous familial adenomatous polyposis or inflammatory bowel disease; 3)Long-term maintenance of systemic immunotherapy with aspirin non-steroidal anti-inflammatory drugs cyclooxygenase 2 inhibitors vitamin D and calcium; 4) those who cannot tolerate colonoscopy; 5) those with poor bowel preparation for colonoscopy or an examination time shorter than 6 minutes; 6)those with combined acute and chronic diseases that may seriously affect the treatment and prognosis such as severe cardiovascular and cerebrovascular diseases and liver and kidney diseases and serious postoperative complications; 7)women who are pregnant or preparing for pregnancy and women who are breastfeeding; 8)Those who are allergic to or have contraindications to the relevant drugs; 9)Those with hidden mental illnesses who are unable to cooperate with the completion of the trial; 10)patients with other malignant tumors at the same time; 11)Patients who are undergoing other clinical trials within 1 month; 12) other conditions that the investigator considers unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
relapse rate;

Secondary

MeasureTime frame
Scores on the Chinese Medicine Criteria Efficacy Scale;The scores of Anxiety ;The scores of Depression ;

Countries

CHINA

Contacts

Public Contactweiwei

Wangjing Hospital China Academy of Traditional Chinese Medicine

sxxtyy@sina.com13601233816

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026